Cipla to expand global footprint, plans investment in its UK subsidiary

Cipla to expand global footprint, plans investment in its UK subsidiary

India, Mumbai, 7th July 2014: Cipla Limited, a global healthcare company, today announced in collaboration with the UK Government, its intention to make investments of up to £100 million in its UK subsidiary over the next few years.

Said The Right Honourable George Osborne, Chancellor ofthe Exchequer, Her Majesty's Government of the United Kingdom: "I am happy to be able to announce that Indian pharmaceutical company Cipla will invest up to £100 million in the UK. The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as well as research and development, clinical trials and further expansion internationally and in the UK.

Cipla is one of India's leading pharmaceutical firms and this decision shows the UK's international strength and attractiveness in this sector as well as its growing importance in Cipla's long term strategy" said the Chancellor.

"On the occasion of the 66th anniversary of the British National Health Service (NHS) Cipla believes that, by providing high quality affordable medicines for patients, it can contribute cost effective solutions for the NHS. We are very pleased to be making this investment in the UK. We were impressed with the pro-active support and engagement that the UK Government and its various ministries showed in attracting Cipla to choose the UK as a key hub in our global footprint" said Mr. Rajesh Garg, Global Chief Financial Officer and member of the board of Cipla.

About Cipla Limited

Cipla is a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one ofthe most respected pharmaceutical names in India as wellas across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contact:

Charlotte Chunawala Jaisingh Balakrishnan

Corporate Communications Corporate Communications

Mobile: +91 7506257377 Mobile: +91 9833836185

E Mail id: [email protected]; E Mail id: [email protected];